Scholars@Duke
Andrew John Armstrong

Andrew John Armstrong

George Barth Geller Distinguished Professor for Research in Cancer
Medicine, Medical Oncology
andrew.armstrong@duke.edu
Duke Box 103861, Durham, NC 27710
GSRB1 Room 3006, 905 La Salle St, Durham, NC 27710
Office hours

Featured Works

A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer.

Journal article Urol Oncol · January 2013 Featured Work OBJECTIVES: Epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinases may be involved in activation of androgen receptor and progression of prostate cancer. They represent potential therapeutic targets in prostate cancer. Lapatinib is an oral inhi ... Full text Link to item Cite

Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy.

Journal article Urol Oncol · September 2012 Featured Work OBJECTIVES: The association of a change in serum alkaline phosphatase (ALP) with overall survival OS in men with metastatic castration-resistant prostate cancer (CRPC) receiving chemotherapy is unknown. We evaluated the association of changes in ALP within ... Full text Link to item Cite

Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer.

Journal article Eur Urol · March 2012 Featured Work CONTEXT: We have recently witnessed a rapid increase in the number of effective systemic agents for men with metastatic castration-resistant prostate cancer (CRPC), including novel hormonal therapies (abiraterone acetate and MDV3100), immunotherapies (sipu ... Full text Link to item Cite

Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer.

Journal article Eur Urol · February 2012 Featured Work BACKGROUND: The optimal number of 3-wk docetaxel plus prednisone (DP) cycles for metastatic castration-resistant prostate cancer (mCRPC) is unclear. OBJECTIVE: A retrospective analysis of two clinical trials was performed to evaluate the association of the ... Full text Link to item Cite

Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study.

Journal article Cancer · January 1, 2012 Featured Work BACKGROUND: To determine the potential efficacy of targeting both the tumor and bone microenvironment in patients with castration-resistant prostate cancer (PC), the authors conducted a phase 1-2 trial combining docetaxel with dasatinib, an oral SRC inhibi ... Full text Link to item Cite

Utilization trends at a multidisciplinary prostate cancer clinic: initial 5-year experience from the Duke Prostate Center.

Journal article J Urol · January 2012 Featured Work PURPOSE: The multidisciplinary approach is becoming increasingly encouraged but little is known about the multidisciplinary experience compared to routine care. For patients with prostate cancer the goal is to provide evaluations by urologists, medical and ... Full text Link to item Cite

Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.

Journal article J Clin Oncol · October 20, 2011 Featured Work PURPOSE: The activity of the novel antitumor agent tasquinimod (TASQ) with S100A9 as a molecular target was investigated in men with metastatic castration-resistant prostate cancer (CRPC) and minimal symptoms. PATIENTS AND METHODS: We conducted a randomize ... Full text Link to item Cite

Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer.

Journal article Prostate Cancer Prostatic Dis · September 2011 Featured Work The management of men with metastatic castration-resistant prostate cancer (CRPC) has taken several leaps forward in the past year, with the demonstration of improved overall survival with three novel agents (sipuleucel-T, cabazitaxel with prednisone and a ... Full text Link to item Cite

The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy.

Journal article Cancer · September 1, 2011 Featured Work BACKGROUND: In men with metastatic castration-resistant prostate cancer (CRPC), the association of measurable tumor responses with overall survival (OS) is unknown. The authors retrospectively evaluated the TAX327 phase 3 trial to study this relation. METH ... Full text Link to item Cite

Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer.

Journal article Prostate Cancer Prostatic Dis · September 2011 Featured Work Although treatment options for men with castration-resistant prostate cancer (CRPC) have improved with the recent and anticipated approvals of novel immunotherapeutic, hormonal, chemotherapeutic and bone-targeted agents, clinical benefit with these systemi ... Full text Link to item Cite

Therapy for non-clear cell histologies in renal cancer.

Journal article Curr Clin Pharmacol · August 2011 Featured Work The advent of targeted systemic therapies has significantly improved treatment options for patients with metastatic renal cell carcinoma (RCC). Multiple agents that inhibit angiogenesis cell growth and proliferation via the VEGF and mTOR (TORC1) pathways h ... Full text Link to item Cite

Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers.

Journal article Mol Cancer Res · August 2011 Featured Work During cancer progression, malignant cells undergo epithelial-mesenchymal transitions (EMT) and mesenchymal-epithelial transitions (MET) as part of a broad invasion and metastasis program. We previously observed MET events among lung metastases in a precli ... Full text Link to item Cite

Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T?

Journal article Clin Med Insights Oncol · 2011 Featured Work Most prostate cancer-related deaths occur in patients with castration-resistant prostate cancer (CRPC). Until recently, only therapy with docetaxel and prednisone has been shown to prolong survival in men with metastatic CRPC. With the United States Food a ... Full text Link to item Cite

Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer.

Journal article Prostate Cancer Prostatic Dis · June 2010 Featured Work In 2009, castration-resistant metastatic prostate cancer continues to account for more deaths in US men than any other cancer apart from lung cancer. Although novel targeted molecular, hormonal and immunologic agents are accelerating in their development i ... Full text Link to item Cite

A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer.

Journal article Clin Cancer Res · June 1, 2010 Featured Work PURPOSE: Given discrepancies between preclinical and clinical observations of mammalian target of rapamycin (mTOR) inhibition in prostate cancer, we sought to determine the pharmacodynamic effects of the mTOR/TORC1 inhibitor rapamycin in men with intermedi ... Full text Link to item Cite

The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival.

Journal article Eur J Cancer · February 2010 Featured Work AIMS OF THE STUDY: There are no known predictive factors of response in men receiving chemotherapy for metastatic castration-resistant prostate cancer (mCRPC). We investigated pre-treatment factors that predicted a 30% PSA decline (30% PSAD) within 3 month ... Full text Link to item Cite

Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer.

Journal article Clin Cancer Res · January 1, 2010 Featured Work PURPOSE: We sought to evaluate predictors of overall survival following progression after systemic chemotherapy in men with metastatic castration-resistant prostate cancer. EXPERIMENTAL DESIGN: For our study population, we used the TAX327 multicenter rando ... Full text Link to item Cite

Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature.

Journal article Oncologist · August 2009 Featured Work Recurrent prostate cancer has a complex molecular etiology and a prolonged disease course. Although initially responsive to androgen ablation, many men eventually become castration resistant, develop skeletal metastases, and are palliatively treated with d ... Full text Link to item Cite

The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer.

Journal article Prostate Cancer Prostatic Dis · 2009 Featured Work The purpose of this study was to evaluate the relationship of baseline body mass index (BMI) and serum testosterone level with prostate cancer outcomes in men with castration-resistant metastatic prostate cancer (CRPC). BMI and testosterone levels were eva ... Full text Link to item Cite

A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer.

Journal article Clin Cancer Res · October 1, 2008 Featured Work PURPOSE: The primary aims of this phase I-II study were to determine the maximum tolerated dose, dose-limiting toxicity, pharmacokinetics, and preliminary efficacy of the combination of docetaxel and the endothelin A receptor antagonist atrasentan as first ... Full text Link to item Cite

NCCN Task Force Report: mTOR inhibition in solid tumors.

Journal article J Natl Compr Canc Netw · September 2008 Featured Work The mammalian target of rapamycin (mTOR) protein complex functions as an integration center for various intracellular signaling pathways involving cell cycle progression, proliferation, and angiogenesis. These pathways are frequently dysregulated in cancer ... Link to item Cite

Clinical endpoints for drug development in prostate cancer.

Journal article Curr Opin Urol · May 2008 Featured Work PURPOSE OF REVIEW: Overall survival remains the benchmark in phase III settings of novel agents in castration-resistant metastatic prostate cancer. This review highlights many of the current potential early measures of response and clinical benefit that ar ... Full text Link to item Cite

New drug development in metastatic prostate cancer.

Journal article Urol Oncol · 2008 Featured Work In 2007, drug development in castration-resistant metastatic prostate cancer (CRPC) remains challenging, due to the number of potentially viable molecular targets and clinical trials available, the lack of established surrogates for overall survival, and c ... Full text Link to item Cite

Cell signaling modifiers in prostate cancer.

Journal article Cancer J · 2008 Featured Work Despite advances in the treatment of hormone-refractory prostate cancer (HRPC) with docetaxel chemotherapy as evidenced by the TAX 327 and SWOG 99-16 trials, therapeutic options remain limited in patients with cancer that progresses while they are receivin ... Full text Link to item Cite

A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis.

Journal article Clin Cancer Res · November 1, 2007 Featured Work PURPOSE: To develop a prognostic model and nomogram using baseline clinical variables to predict death among men with metastatic hormone-refractory prostate cancer (HRPC). EXPERIMENTAL DESIGN: TAX327 was a clinical trial that randomized 1,006 men with meta ... Full text Link to item Cite

Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer.

Journal article J Clin Oncol · September 1, 2007 Featured Work PURPOSE: It is currently unclear if early prostate-specific antigen (PSA) or pain improvements are adequate surrogates for overall survival in men with metastatic hormone-refractory prostate cancer (HRPC). Here we examined various degrees of PSA decline an ... Full text Link to item Cite

Anti-angiogenic therapy in renal cell cancer.

Journal article BJU Int · May 2007 Featured Work Angiogenesis is an important hallmark of RCC, reflected in the natural history, Histology, genetics and now therapeutics of this disease. Clearly, the pro-angiogenic growth factor VEGF is a functional drug target in RCC and many strategies to inhibit this ... Full text Link to item Cite

Systemic strategies for prostate cancer.

Journal article Minerva Urol Nefrol · March 2007 Featured Work Systemic therapy beyond hormonal therapy for advanced prostate cancer includes chemotherapy, antiangiogenic therapy, signal transduction inhibitors, immunomodulatory therapy, and other experimental therapeutics. This review will discuss the state of system ... Link to item Cite

Current standard and investigational approaches to the management of hormone-refractory prostate cancer.

Journal article Rev Urol · 2007 Featured Work Prostate cancer is a common cause of death in men and remains incurable in the metastatic setting. In 2004, 2 landmark trials using docetaxel-based chemotherapy, TAX 327 and SWOG 99-16, showed a survival benefit for the first time in metastatic, hormone-re ... Link to item Cite

New drugs in prostate cancer.

Journal article Curr Opin Urol · May 2006 Featured Work PURPOSE OF REVIEW: The survival of hormone-refractory metastatic prostate cancer patients has improved with the use of docetaxel-based chemotherapy. The survival benefits, however, are modest suggesting that rationally designed therapeutic approaches are n ... Full text Link to item Cite

Advanced prostate cancer: the future.

Journal article Can J Urol · June 2005 Featured Work The demonstration of a survival benefit with docetaxel for the treatment of metastatic hormone refractory prostate cancer (HRPC) is an important step forward in advancing treatment options for advanced prostate cancer. While docetaxel-based therapy has dem ... Link to item Cite

Chemotherapy for advanced prostate cancer: results of new clinical trials and future studies.

Journal article Curr Oncol Rep · May 2005 Featured Work Our understanding of the role of chemotherapy for advanced prostate cancer has improved considerably in 2004 with the publication of two large randomized phase III trials and the approval by the US Food and Drug Administration of docetaxel and prednisone f ... Full text Link to item Cite

Novel therapeutic approaches to advanced prostate cancer.

Journal article Clin Adv Hematol Oncol · April 2005 Featured Work Considerable progress in the treatment of advanced prostate cancer was made in 2004 with the approval by the US Food and Drug Administration of docetaxel for the treatment of metastatic hormone-refractory prostate cancer. The survival benefit with docetaxe ... Link to item Cite

Inertial properties and loading rates affect buckling modes and injury mechanisms in the cervical spine.

Journal article J Biomech · February 2000 Featured Work Cervical spine injuries continue to be a costly societal problem. Future advancements in injury prevention depend on improved physical and computational models which, in turn, are predicated on a better understanding of the responses of the neck during dyn ... Full text Link to item Cite

Mutagenic analysis of functional domains of the mos proto-oncogene and identification of the sites important for MAPK activation and DNA binding.

Journal article Oncogene · October 19, 1995 Featured Work We constructed in-frame deletion/replacement mutations in the Xenopus mos proto-oncogene that lie within conserved Mos-specific codons, but outside of the regions that are conserved among the src kinase family of genes. All gene products were assayed in vi ... Link to item Cite